High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment

The impact of drug–drug interactions (DDI) between ritonavir-boosted lopinavir (LPV-r) to treat patients with coronavirus disease 2019 (COVID-19) and commonly used drugs in clinical practice is not well-known. Thus, we evaluated the rate and severity of DDI between LPV-r for COVID-19 treatment and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Macías, Juan, Pinilla, Ana, Lao-Dominguez, Francisco A., Corma, Anaïs, Contreras-Macias, Enrique, González-Serna, Alejandro, Gutierrez-Pizarraya, Antonio, Fernández-Fuertes, Marta, Morillo-Verdugo, Ramón, Trigo, Marta, Real, Luis M., Pineda, Juan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708981/
https://www.ncbi.nlm.nih.gov/pubmed/33262433
http://dx.doi.org/10.1038/s41598-020-78029-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708981/
https://www.ncbi.nlm.nih.gov/pubmed/33262433
http://dx.doi.org/10.1038/s41598-020-78029-3

Ejemplares similares